IMMUNIC, INC.
IMMUNIC, INC. (IMUX): 4 pipeline candidates · 2 upcoming catalysts · ~33 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
32.5 months
D/E 0.25 · 121% dilution
Lead: Phase 3
4 candidates
2 upcoming, next in ~2632d
N/A
A transparent, data-derived signal for IMMUNIC, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$193.4M
Cash
$186.6M
Quarterly Burn
$17.3M
Runway
32.5 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| imu-381 | Phase 3 |
| imu-838 | Phase 3 |
| imu-856 | Phase 3 |
| vidofludimus | Phase 3 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$1.1M
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 952,966 | $1.1M |
| caldwell sutter capital, inc. | 3 | $3 |
| parallel advisors, llc | 2 | $2 |
Frequently asked questions
How many drug candidates are in IMMUNIC, INC.'s pipeline?
IMMUNIC, INC. (IMUX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IMMUNIC, INC.'s lead drug candidate?
IMMUNIC, INC.'s most advanced tracked candidate is imu-381 (Phase 3) for gastrointestinal diseases.
What is IMMUNIC, INC.'s next catalyst?
IMMUNIC, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Toler" — expected September 1, 2033.
What is IMMUNIC, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IMMUNIC, INC. has approximately 32.5 months of cash runway.
What is IMMUNIC, INC.'s market capitalization?
IMMUNIC, INC.'s market capitalization is approximately $193.4M.
Get the full picture on IMMUNIC, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.